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Endodermal sinus tumor (Yolk sac tumor) is the second most
common germ cell malignancy of the ovary accounting for 20–25%
of malignant germ cell tumors. These are rare tumors noting that
ovarian germ cell malignancies comprise only 2–3% of ovarian
cancers. The most common presenting symptoms for patients with
endodermal sinus tumors are a rapidly enlarging mass and pain. The
median age of presentation in one series is 19 and the oldest reported
patient is 75 years old (Bailey and Church, 2005). We report the
oldest known patient with a pure endodermal sinus tumor.
Case report
An 86 year old gravida 4, para 4 woman with a history of lympho-
ma presented to her local oncologist with a 3 month history of ab-
dominal pain and increasing vaginal prolapse. A computed
tomography (CT) scan demonstrated a 5 cm pelvic mass. The patient
underwent a laparoscopic biopsy of the mass at her local hospital
which demonstrated a pathologic diagnosis of endodermal sinus
tumor of the ovary. She was referred to our institution for gynecologic
oncology consultation and management. She reported increasing
pelvic pain, pessary use for vaginal prolapse, and urinary hesitancy.
Her past medical history was signiﬁcant for a hysterectomy. She had
no other medical co-morbidities. Her family history was negative for
cancer. At gynecologic oncology referral she was found to have a
rapidly enlarging 8 cm pelvic mass, markedly larger than noted at⁎ Corresponding author. Fax: +1 704 355 2779.
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revealed a growing mass in the pelvis with intra-abdominal metasta-
ses. The patient underwent an exploratory laparotomy, bilateral
salpingo-oophorectomy, omentectomy, pelvic peritoneal stripping
and left retroperitoneal tumor resection, completing an optimal
cytoreductive procedure. Surgical ﬁndings included a mass arising
from the left ovary ﬁxed to the pelvic sidewall, sub-centimeter
tumor nodules on the colon and small intestine mesentery, and
tumor involving the omentum, representing stage IIIC disease.
Alpha-fetoprotein (AFP) level at diagnosis was noted to be 7010 ng/
mL. Pathology conﬁrmed pure endodermal sinus tumor of the ovary
consistent with the previous biopsies. After an uneventful post-
operative recovery the patient was treated with 4 cycles of bleomy-
cin, etoposide and cisplatin (BEP) chemotherapy. Complications of
chemotherapy included 1 episode of febrile neutropenia, grade 4
thrombocytopenia, grade 4 anemia, and grade 4 hypomagnesemia
and hypokalemia. All toxicity was managed effectively with support-
ive care. At the completion of BEP therapy, a CT scan showed no resid-
ual tumor and the AFP level was 7.1 ng/mL.
Pathology
Pathology from the initial right ovarian biopsy showed a high-
grade malignant neoplasm with complex pattern of anastomosing
channels and spaces, papillary structures and scattered Schiller–
Duval bodies. The tumor cells demonstrated immunoreactivity for
sal-like protein 4, alpha-fetoprotein and glycipan-3 and absent
immunoreactivity for cytokeratin 7, estrogen receptor and octamer-
binding transcription factor 4. The histology and immunophenotype
were diagnostic of pure yolk sac tumor (endodermal sinus tumor).
Pathology from the second surgical procedure showed similar histol-
ogy, pure yolk sac tumor, with involvement of right ovary, left ovary,
colon epiploic tissue, omentum and small bowel.
Discussion
There have been ﬁve other documented cases of pure endodermal
sinus tumors in women over 50 years of age, two of which were in
their sixth decade, two in their seventh decade and one 75 year-old
woman (Brown and Green, 1976; Ferracini et al., 1979; Kinoshita,
1990; Oh et al., 2001; Pliskow, 1993). Four of these women had
pure endodermal sinus tumors of the ovary, and one was extra-
ovarian in origin (Oh et al., 2001). There have been limited case re-
ports of post-menopausal women diagnosed with pure endodermal
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tumor within endometriosis, endometrioid carcinoma, or mucinous
cystadenoma of the ovary have been reported (Lopez et al., 2003).
These cases challenge the theory that pure endodermal sinus tumors
originate only from germ cells, and present the possibility that they
may originate from somatic mesodermal cells, a sort of retrodifferen-
tiation or neometaplastic process. This is supported by the ﬁnding of
positive AFP staining and elevated serum AFP levels in cases of carci-
nomas of somatic origin (Talerman and Vang, 2011).
Cases of pure or mixed endodermal sinus tumors of the ovary
occurring in post-menopausal women are rare. There is limited data
regarding the natural course of the disease, prognostic factors, or
tumor response to therapy. In one retrospective analysis of premeno-
pausal women diagnosed with endodermal sinus tumors, age was not
a signiﬁcant prognostic factor, nor was the presence or absence of ad-
ditional histological elements or lymph node dissection (Nawa et al.,
2001). Before the introduction of effective chemotherapy, the prog-
nosis for patients with malignant germ cell (non-dysgerminoma) tu-
mors was poor, with a 3 year survival rate of 13% for malignant
endodermal sinus tumors. The establishment of BEP chemotherapy
for malignant germ cell tumors has signiﬁcantly improved outcomes.
A Gynecologic Oncology Group (GOG) study treated 93 patients with
malignant germ cell tumors with BEP chemotherapy. Ninety-one pa-
tients were disease-free at a median of 38 months. None of the 25 pa-
tients with endodermal sinus tumors developed recurrence (Williams
et al., 1994). Additional series noted a 76% 5-year disease-free surviv-
al for non-dysgerminoma stage III and IV germ cell tumors treated
with BEP (Bailey and Church, 2005). Ovarian endometrioid carcino-
mas with endodermal sinus tumor components have typically not
responded to cisplatin-based chemotherapy regimens. These mixed
tumors represent an aggressive variant of ovarian malignancy associ-
ated with a rapid growth pattern and high stage at diagnosis. The che-
mosensitivity of the component of the endodermal sinus tumor
patterns has tended to determine pathological recurrence, and a ma-jority of cases of ovarian endodermal sinus tumor associated with
endometrioid or mucinous neoplasms in postmenopausal women
have resulted in death secondary to disease (Nawa et al., 2001). Of
the documented cases of pure endodermal sinus tumors in post-
menopausal women, ﬁnal outcomes were not consistently reported.
Patients often experienced a laboratory response but subsequently
died of disease several months after initial diagnosis. To our knowl-
edge, this is the oldest case of an ovarian endodermal sinus tumor
reported in the literature demonstrating a complete serologic and
clinical response to BEP chemotherapy following surgical debulking.
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